Medical Manufacturing Technologies Acquires Ireland-Based Somex Automation

Medical Manufacturing Technologies, Inc. (MMT), a portfolio company of Arcline Investment Management and a leading global provider of medical device manufacturing solutions, announced the acquisition of Somex Automation (Somex), an Ireland-based provider of custom automation equipment and processes for the medical device manufacturing industry. The Somex product offering will go to market under our MMT Automation brand.

As part of the transaction, Medical Manufacturing Technologies welcomes 34 new employees who will continue to operate out of Somex’s Cork and Ballyvourney facilities in Ireland.

“The acquisition of Somex Automation is a milestone for our company,” said Robbie Atkinson, CEO of Medical Manufacturing Technologies. “We are excited to bring a strong business with highly skilled employees into our family.” Atkinson went on to highlight how the automation and process integration expertise of Somex will become a flagship offering of the MMT Automation brand. “This transaction allows MMT to seamlessly integrate our end-to-end medical device manufacturing to further support our customers on their quest to increase production and expand their ‘lights out’ operation capabilities. The Somex team’s expertise and history of implementation is an asset to our customers.”

“This transaction allows us to grow the bespoke automation and integration solutions offered to medical device manufacturers across the globe,” said Michael Wall, Managing Director and founder of Somex. “We will be able to leverage the strengths of both companies and create an even more powerful offering for our customers.” Wall will join MMT as technical director.

Atkinson stated that MMT launched MMT Automation to streamline its subsidiaries’ automation offerings, further positioning Somex Automation solutions to customers across its portfolio.

“As a global leader of medical device manufacturing equipment and processes, we streamlined shared technologies and processes to ensure our customers have access to the solutions they need when they need them,” said Atkinson. “MMT Automation aligns our automation expertise across the portfolio where we can most effectively help our customers create autonomous manufacturing and continuous optimization of production lines.”

MMT offers its customers a broad portfolio of high-precision solutions for developing and manufacturing complex medical devices used in minimally invasive procedures. Its robust offering expands beyond equipment to proof-of-concept, process development, and TotalCare aftermarket support and services.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”